In the News
Press Releases
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
FRAMINGHAM, Mass., January 7, 2020 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative [...]
Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning
Industry veteran brings broad commercial expertise in neuroscience drug development and commercialization as Alzheon advances ALZ-801 into Phase 3 as potentially the first oral disease-modifying treatment [...]
Alzheon Announces Scientific Presentation at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Taking Place on December 4-7 in San Diego, USA
New Data Shows Significantly Higher Rate of Cortical Thickness Loss in Early Alzheimer’s Patients with APOE4/4 GenotypeCortical Thickness May Be a Useful Biomarker in Future Disease Modification [...]
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course Publication Outlines Therapeutic Characteristics [...]
Alzheon Presents Data on the Discovery of 3-SPA, an Endogenous Substance in the Human Brain, at the Alzheimer’s Association International Conference
3-SPA, also a Product of ALZ-801, Prevents Formation of Toxic Beta Amyloid Oligomers, the Key Driver of Alzheimer’s Disease FRAMINGHAM, Mass., July 14, 2019 – Alzheon, Inc., a [...]
Alzheon to Make Presentations at Upcoming Industry Conferences
Keynote Lectures at Neurotech, China Focus and Alzheimer’s Solutions Conference FRAMINGHAM, Mass., May 13, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio [...]